SEOUL (Reuters) -South Korea is turning to additional pharmaceutical tools as it looks to pre-empt a surge of COVID-19 omicron infections, authorising the use of Novavax Inc’s vaccine on Wednesday and preparing to distribute the first of Pfizer’s antiviral pills. Read full story



